Research
Hormonal
Tirzepatide likely increases the number of people achieving a 5% weight reduction (risk ratio 3.60, 95% CI 2.44 to 5.30) compared to placebo.
Tirzepatide may be particularly effective for helping patients achieve significant weight loss goals.
StrongSupportsmedium confidence
Tirzepatide likely results in an increase in the number of people achieving a 5% weight reduction (risk ratio (RR) 3.60, 95% CI 2.44 to 5.30; I2 = 86%; 5 studies, 4455 participants; moderate-certainty evidence).
Why this rating
Based on meta-analysis of randomized controlled trials.
Source
Tirzepatide for adults living with obesity
Juan Víctor Ariel Franco et al. · Cochrane Database of Systematic Reviews · 2025
Meta-analysisCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →